Siamab’s sugar-targeted mAbs yield a lead program and Boehringer deal
Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal with Boehringer and a pathway to companion diagnostics.
The biotech is now disclosing the first fruits of its platform, with three presentations in the last month on ST1 ADC, an antibody-drug conjugate (ADC) in preclinical testing for solid tumors, slated to enter the clinic in 2019.
Cancer cells have long been known to harbor proteins differently glycosylated from those in normal cells, but the difficulty has been in developing high-affinity therapies that target individual sugars specifically.
Others in the field have developed mAbs against tumor-associated sugars found on multiple cell surface proteins, or against specific cell surface glycoproteins that distinguish tumor cells from normal cells (see “mAb About Sugar”).
Table: mAb about sugar
At least four companies have disclosed active programs targeting tumor-associated carbohydrate antigens or